px-104
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT01998659)
Timeline
Indications
Mechanism of action
- Bile acid receptor FXRAGONIST
NR1H4 agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)c1ccc([C@H]2C[C@@H]2c2ccc(OCc3c(-c4c(Cl)cccc4Cl)noc3C3CC3)cc2Cl)cc1- Mol. weight
- 554.86 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3822773 ↗
- ChEMBLCHEMBL3545113 ↗
Also known as
- px-102
- px-102
- px-102
- px-104
- px-104
- px-104
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01999101 | Phase 2 | Oct 1, 2013 | Phenex Pharmaceuticals, University of Vienna |
| NCT01998672 | Phase 1 | Feb 1, 2012 | Phenex Pharmaceuticals |
| NCT01998659 | Phase 1 | Sep 1, 2011 | Phenex Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Phenex Pharmaceuticals | For profit | 3 | 3 | 2 | 2011 |
| University of Vienna | Academic/Hospital | 1 | 0 | 1 | 2013 |
2 organizations
Page 1 / 1